EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy

Lignende værker

• Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
  af: Oya, Yuko, et al.
  Udgivet: (2021)
• Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
  af: Zhang, Shirong, et al.
  Udgivet: (2015)
• Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
  af: Lee, Sang Hoon, et al.
  Udgivet: (2020)
• A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer
  af: Lammers, Philip E., et al.
  Udgivet: (2014)
• The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
  af: Cheng, Wen-Chien, et al.
  Udgivet: (2021)